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INTRODUCTION 
 
          Diabetes mellitus is a leading non communicable disease of the world. As 
per in International diabetes federation 2013 our country has the second largest  
diabetic population of about 65.1 million next to China 98.4 million. There are 
convincing evidences in the literature which show the stead rise in the incidence 
of this disease in India. With the advancement in the modern science and 
technology there is a steady decrease in the communicable diseases but there is 
also  increase in the non communicable diseases in developing countries like 
India.with this advancements in early diagnosis and treatment there is a normal 
life expectancy of 50-60 years. Though there  is a steady increase in life 
expectancy, the morbidity due to these  non communicable diseases remains 
great economic & social burden to community which leads to evolvement of 
strategies to control the disease complications. 
          Diabetes is one of the important non communicable disease of  the 
modern era, which leads to multi system involvement  i.e 
cardiac,nervous,renal,ophthalmic,genito urinal, gastro intestinal,dermatological 
etc. Although diabetes is a multi systemic disorder its pulmonary involvement is 
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not extensively studied. Pathological studies in diabetic patients have 
represented changes in alveolar epithelium and capillaries. 
 The consequence is development of obstructive or restrictive disorders. 
Histopathological changes in lungs of diabetic patients are due to collagen and 
elastin alterations and microangiopathy .These changes become the cause of 
pulmonary dysfunctions.” If diabetes is detected early and adequate steps are 
taken, it may be possible to significantly delay the occurrence of complications 
and there after their progression.” 
       “ Although a lot of research is going on the effects of Diabetes Mellitus on 
pulmonary function tests all over the world, the literature supporting to this is 
not in abundance in India. Therefore this study was undertaken to find out the 
correlation between duration of type 2 DM and PFTs in diabetic patients who 
attended or admitted to medical OPD or wards” of government rajaji hospital, 
Madurai.   
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AIMS AND OBJECTIVES : 
             “The present study is conducted to find  the relation between duration of 
diabetes and its impairment of pulmonary function tests (PFT) in Type 2 DM 
patients.” 
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REVIEW OF LITERATURE 
 
“Pulmonary function testing is a useful tool for evaluating the respiratory 
system, in addition to the history, imaging studies, and invasive investigations 
such as bronchoscopy and open-lung biopsy. By comparing the measured 
pulmonary function test values of the patient at any particular point with values 
derived from population studies is useful in identifying the pathology.”  
 
“The percentage of predicted normal is used to grade the severity of the 
abnormality. Now a days pulmonary function testing is often used in  medicine 
for evaluating respiratory symptoms, preoperative assessment, and for 
diagnosing diseases such as asthma and chronic obstructive pulmonary disease.” 
 
 
“Pulmonary function tests (PFTs) is a term used to indicate a battery of 
manoeuvres that are performed using standardized instrument to measure lung 
function. PFTs can include screening spirometry, lung volume measurement, 
diffusing capacity for carbon monoxide, and arterial blood gases, which may be 
collectively referred to as a complete pulmonary function survey.”  
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Physiology  
  
The standard lung volumes and capacities. Typical values for a 70-kg adult are 
shown above 
 
“Alveolar ventilation is the exchange of gas between the alveoli and the external 
environment. It is the process by which oxygen is brought into the lungs from 
the atmosphere and by which the carbon dioxide carried into the lungs from the 
mixed venous blood is expelled from the body. Alveolar ventilation is defined 
as the volume of fresh air entering the alveoli per minute. It is usually expressed 
in litres per min.” 
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The Lung Volumes 
 
“The volume of gas in the lungs at any instant depends on the mechanics of the 
lungs and chest wall and the activity of the muscles of inspiration and 
expiration. The lung volume under any specified set of conditions can be altered 
by pathologic and normal physiologic processes. Standardization of the 
conditions under which lung volumes are measured allows comparisons to be 
made among subjects or patients. The size of a person's lungs depends on height 
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and weight or body surface area, age and sex. Therefore, the lung volumes for a 
patient are usually compared with data of "predicted" lung volumes matched to 
age, sex, and body size.” 
 
The Tidal Volume 
“The tidal volume (TV) is the volume of air entering or leaving the lungs for 
each respiratory cycle (1). It is determined by the activity of the respiratory 
control centres in the brain as they affect the respiratory muscles and by the 
mechanics of the lung and the chest wall. During  eupnea  (normal, quiet 
breathing) the TV of a 70-kg adult is about 500 mL per breath, but this volume 
can increase dramatically during exercise.” 
 
 
The Residual Volume 
“The residual volume (RV) is the volume of air remaining in the lungs after a 
maximal forced expiration(2). It is determined by the muscles of expiration and 
the inward elastic recoil of the lungs as they oppose the outward elastic recoil of 
the chest wall. Dynamic compression of the airways during the forced 
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expiratory effort may also be an important determinant of the RV as airway 
collapse occurs, thus trapping gas in the alveoli. The RV of a healthy 70-kg 
adult is about 1.5 L, but it can be much greater in a disease state such as 
emphysema, in which inward alveolar elastic recoil is diminished and much 
airway collapse and gas trapping occur. The RV is important to a healthy person 
because it prevents the lungs from collapsing at very low lung volumes. Such 
collapsed alveoli would require great inspiratory efforts to return to  normal 
position .” 
 
The Expiratory Reserve Volume 
“The expiratory reserve volume (ERV) is the volume of gas that is expelled 
from the lungs during a maximal forced expiration that starts at the end of a 
normal tidal expiration(3). It is therefore determined by the difference between 
the functional residual capacity (FRC) and the RV. The ERV is about 1.5 L in a 
healthy 70-kg adult.” 
The Inspiratory Reserve Volume 
“The inspiratory reserve volume (IRV) is the volume of gas that is inhaled into 
the lungs during a maximal forced inspiration starting at the end of a normal 
tidal inspiration(2). It is determined by the strength of contraction of the 
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inspiratory muscles, the inward elastic recoil of the lung and the chest wall, and 
the starting point, which is the FRC plus the VT. The IRV of a normal 70-kg 
adult is about 2.5 L.” 
The Functional Residual Capacity 
“The functional residual capacity (FRC) is the volume of gas remaining in the 
lungs at the end of a normal tidal expiration(2). Because it was traditionally 
assumed that no muscles of respiration are contracting at the end of a normal 
tidal expiration, the FRC is usually considered to represent the balance point 
between the inward elastic recoil of the lungs and the outward elastic recoil of 
the chest wall.” 
“However, the respiratory muscles may have significant tone at the FRC, and in 
certain circumstances the FRC may be greater than or even less than the lung 
volume of the totally relaxed respiratory system. Thus, the lung volume at 
which the inward elastic recoil of the lungs is equal and opposite to the outward 
elastic recoil of the chest wall is sometimes referred to as the relaxation volume 
of the respiratory system. The FRC may be greater than the relaxation volume if 
the next inspiration occurs before the relaxation volume is reached, either 
because of high breathing rates or high resistance to expiratory airflow in the 
larynx or peripheral airways; or active contraction of the inspiratory muscles at 
end expiration. Either or both of these may occur in babies, who have higher 
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FRCs than would be predicted from the great inward elastic recoil of their lungs 
and the small outward recoil of their chest walls. During exercise, the FRC may 
be lower than the relaxation volume because of active contraction of the 
expiratory muscles.” 
“The FRC consists of the RV plus the ERV. It is about 3 L in a healthy 70  
kilogram adult.” 
The Inspiratory Capacity 
“The inspiratory capacity (IC) is the volume of air that is inhaled into the lungs 
during a maximal inspiratory effort that begins at the end of a normal tidal 
expiration (the FRC)(3). It is therefore equal to the VT plus the IRV. The IC of 
a normal 70-kg adult is about 3 L.” 
 
The Total Lung Capacity 
“The total lung capacity (TLC) is the volume of air in the lungs after a maximal 
inspiratory effort(2). It is determined by the strength of contraction of the 
inspiratory muscles and the inward elastic recoil of the lungs and the chest wall. 
The TLC consists of all four lung volumes: the RV, the VT, the IRV, and the 
ERV. The TLC is about 6 L in a healthy 70-kg adult.” 
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The Vital Capacity 
“The vital capacity (VC), is the volume of air expelled from the lungs during a 
maximal forced expiration starting after a maximal forced inspiration(1). The 
VC is therefore equal to the TLC minus the RV, or about 4.5 L in a healthy 70-
kg adult. The VC is also equal to the sum of the VT and the IRV and ERV. It is 
determined by the factors that determine the TLC and RV.” 
Airways Resistance 
“Several factors besides the elastic recoil of the lungs and the chest wall must be 
overcome to move air into or out of the lungs.” These factors include the inertia 
of the respiratory system, the frictional resistance of the lung and chest wall 
tissue, and the frictional resistance of the airways to the flow of air. The inertia 
of the system is negligible. Pulmonary tissue resistance is caused by the friction 
encountered as the lung tissues move against each other as the lung expands. 
The airways resistance plus the pulmonary tissue resistance is often referred to 
as the pulmonary resistance. Pulmonary tissue resistance normally contributes 
about 20% of the pulmonary resistance, with airways resistance responsible for 
the other 80%. Pulmonary tissue resistance can be increased in such conditions 
as pulmonary sarcoidosis and fibrosis. Airway resistance is the major 
component of the total resistance and because it can increase tremendously both 
in healthy people and in those suffering from various diseases. 
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Generally, the relationship among pressure, flow, and resistance is stated as 
Pressure Difference = Flow x Resistance 
Therefore, 
Resistance = Pressure Flow[cm of H20]/ Flow[litres/s]  
This means that resistance is a meaningful term only during flow. 
Understanding and quantifying the resistance to airflow in the conducting 
system of the lungs is difficult because of the nature of the airways themselves. 
It is relatively easy to inspect the resistance to airflow in a single, unbranched, 
indistensible tube; however, the ever-branching, narrowing, distensible, and 
compressible system of airways makes analysis of the factors contributing to 
airways resistance especially complicated. Therefore, equations can only 
approximate what is really happening clinically. 
 
When a fluid such as air flows through rigid, smooth-bore tubes, its behaviour is 
governed by Poiseuille's law. The pressure difference is directly proportional to 
the product of flow and resistance: 
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∆P α VR 
where P = pressure difference  
V= airflow  
R = resistance 
According to Poiseuille's law, the “resistance is directly proportional to the 
viscosity of the fluid and the length of the tube and is inversely proportional to 
the fourth power of the radius of the tube.” 
 
 
l = length of tube  
r = radius of tube 
Note that if the radius is halved, the resistance increases by 16 times because the 
resistance is inversely proportional to the fourth power of radius . 
Flow changes from laminar to turbulent when Reynolds' number exceeds 2000. 
Reynolds' number is equal to the product of density and the velocity of the fluid 
∆ 
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and the diameter of the tube divided by the viscosity of the fluid. It does not 
have unit. 
 
 
 
 
During turbulent flow, the relationship among the pressure difference, flow, and 
resistance changes. Because the pressure difference is proportional to the flow 
squared, much greater pressure differences are required to generate the same 
airflow. The resistance term is influenced more by the density than it is by the 
viscosity during turbulent flow: 
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Transitional flow is a mixture of laminar and turbulent flow. This type of flow 
often occurs at branch points or points distal to partial obstructions. 
“Turbulent flow tends to occur if airflow is high, gas density is high, the tube 
radius is large, or all three conditions exist. True laminar flow probably occurs 
only in the smallest airways, where the linear velocity of airflow is extremely 
low”. Linear velocity (cm/s) is equal to the flow (cm3/s) divided by the cross-
sectional area. The total cross-sectional area of the smallest airways is very 
large, and so the linear velocity of airflow is very low. The airflow in the trachea 
and larger airways is usually either turbulent or transitional. 
 
Distribution of Airways Resistance 
“About 25–40% of the total resistance to airflow is located in the upper airways: 
the nose, nasal turbinates, oropharynx, nasopharynx, and larynx. Resistance is 
higher when one breathes through the nose than when one breathes through the 
mouth.” 
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The vocal cords open slightly during normal inspirations and close slightly 
during expirations. During deep inspirations, they open widely. The muscles of 
the oropharynx also contract during normal inspirations, which dilates and 
stabilizes the upper airway. During deep forced inspirations, the development of 
negative pressure could cause the upper airway to be pulled inward and partly or 
com-pletely obstruct airflow. Reflex contraction of these pharyngeal dilator 
muscles normally keeps the airway open. 
“As for the tracheobronchial tree, the component with the highest individual 
resistance is obviously the smallest airway, which has the smallest radius. 
Nevertheless, because the smallest airways are arranged in parallel, their 
resistances add as reciprocals, so that the total resistance to airflow offered by 
the numerous small airways is extremely low during normal, quiet breathing. 
Therefore, under normal circumstances the greatest resistance to airflow resides 
in the medium-sized bronchi.” 
 
 
“Lung Volume & Airways Resistance” 
Airways resistance decreases with increasing lung volume, as shown in Figure 
(normal curve). This relationship is still present in an emphysematous lung, 
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although in emphysema the resistance is higher than that in a healthy lung, 
especially at low lung volumes. 
 
 
“Relationship between lung volume and airways resistance. Total lung capacity” 
is at right; residual volume is at left.  
Solid line = normal lung; dashed line = abnormal (emphysematous) lung 
 
There are two reasons for this relationship; both mainly involve the small 
airways which, have little or no cartilaginous support. “The small airways are 
therefore rather distensible and also compressible.” “Thus the transmural 
pressure gradient across the wall of the small airways is an important 
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determinant of the radius of the airways. Since resistance is inversely 
proportional to the fourth power of radius, changes in the radii of small airways 
can cause dramatic changes in airways resistance, even with so many parallel 
pathways.” “To increase lung volume, a person breathing normally takes a 
"deep breath," that is, makes a strong inspiratory effort.” “This effort causes 
intrapleural pressure to become much more negative than the –7 or –10 cm H2O 
seen in a normal, quiet breath. The transmural pressure gradient across the wall 
becomes much more positive, and small airways are distended.” 
“A second reason for the decreased airways resistance seen at higher lung 
volumes is that the “increase in traction on smaller airways.” The small airways 
traveling through the lung form attachments to the walls of alveoli. As the 
alveoli expand during the course of a “deep inspiration, the elastic recoil in their 
walls increases; this elastic recoil is transmitted to the attachments at the airway, 
pulling it open.” 
 
 
Assessment of Airways Resistance 
The resistance to airflow cannot be measured directly but must be calculated 
from the pressure gradient and airflow during a breath:  
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This formula is an approximation because it presumes that all airflow is laminar, 
which is not true. But there is a second problem: How can the pressure gradient 
be determined? 
To know the pressure gradient, the alveolar pressure—which also cannot be 
measured directly—must be known. Alveolar pressure can be calculated using a 
body plethysmograph, an expensive piece of equipment, but this procedure is 
not often done. Instead, airways resistance is usually assessed indirectly. The 
assessment of airways resistance during expiration will be emphasized because 
that factor is of interest in patients with emphysema, chronic bronchitis, and 
asthma. 
 
Measurement of the Lung Volumes 
“Measurement of the lung volumes is important clinically because many 
pathologic states can alter specific lung volumes or their relationships to one 
another. The lung volumes, however, can also change for normal physiologic 
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reasons. Changing from a standing to a supine posture decreases the FRC 
because gravity is no longer pulling the abdominal contents away from the 
diaphragm. This decreases the outward elastic recoil of the chest wall. The RV 
and TLC do not change significantly when a person changes from standing to 
the supine position. If the FRC is decreased, then the ERV will also decrease 
and the IRV will increase. The VC, RV, and TLC may decrease slightly because 
some of the venous blood that collects in the lower extremities and the abdomen 
when a person is standing returns to the thoracic cavity when that person lies 
down.”  
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Illustration of alterations in the lung volumes and capacities that occur when a 
subject changes from the standing to the supine position. 
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Illustration of typical alterations in the lung volumes and capacities in restrictive 
and obstructive diseases. 
 
“Battery of manoeuvre’s 
Pulmonary function studies use a variety of manoeuvre’s to measure and record 
the properties of four lung components. These include the  
--airways (large and small),  
--lung parenchyma (alveoli, interstitium),  
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--pulmonary vasculature, and  
--the bellows-pump mechanism.  
Various diseases can affect each of these components. 
Spirometry: 
Spirometry is the most commonly used lung function screening study. It 
generally should be the clinician's first option, with other studies being reserved 
for specific indications. Most patients can easily perform spirometry when 
coached by an appropriately trained technician or other health care provider. 
The test can be administered in the ambulatory setting, physician's office, 
emergency department, or inpatient setting. The indications for spirometry are 
diverse” 
 
 
 
“Indications for Spirometry 
Diagnostic 
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To evaluate symptoms 
 Chest pain 
 Cough 
 Dyspnea 
 Orthopnea 
 Phlegm production 
 Wheezing 
To evaluate signs 
 Chest deformity 
 Cyanosis 
 Diminished breath sounds 
 Expiratory slowing 
 Overinflation 
 Unexplained crackles 
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To evaluate abnormal laboratory tests 
 Abnormal chest radiographs 
 Hypercapnia 
 Hypoxemia 
 Polycythemia 
To measure the effect of disease on pulmonary function 
To screen persons at risk for pulmonary diseases 
 Smokers 
 Persons in occupations with exposures to injurious substances 
Some routine physical examinations 
 To assess preoperative risk 
 To assess prognosis (lung transplant, etc.) 
 To assess health status before enrollment in strenuous physical activity 
programs 
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Monitoring 
To assess therapeutic interventions 
 Bronchodilator therapy 
 Steroid treatment for asthma, interstitial lung disease, etc. 
 Management of congestive heart failure 
 Other (antibiotics in cystic fibrosis, etc.) 
To describe the course of diseases affecting lung function 
 Pulmonary diseases 
 Obstructive small airway diseases 
 Interstitial lung diseases 
 Cardiac diseases 
 Congestive heart failure 
 Neuromuscular diseases 
 Guillain-Barré syndrome 
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To monitor persons in occupations with exposure to injurious agents 
To monitor for adverse reactions to drugs with known pulmonary toxicity 
Evaluation of Disability or Impairment 
To assess patients as part of a rehabilitation program 
 Medical 
 Industrial 
 Vocational 
To assess risks as part of an insurance evaluation 
To assess persons for legal reasons 
 Social Security or other government compensation programs 
 Personal injury lawsuits 
 Other 
Public Health 
 Epidemiologic surveys 
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 Comparison of health status of populations living in different 
environments 
 Validation of subjective complaints in occupational or environmental 
settings 
 Derivation of reference equations” 
 
“Spirometry requires a voluntary manoeuvre in which a seated patient inhales 
maximally from tidal respiration to total lung capacity and then rapidly exhales 
to the fullest extent until no further volume is exhaled at residual volume. The” 
“manoeuvre may be performed in a forceful manner to generate a forced vital 
capacity (FVC) or in a more relaxed manner to generate a slow vital capacity 
(SVC). In normal persons, the inspiratory vital capacity, the expiratory SVC, 
and expiratory FVC are essentially equal. However, in patients with obstructive 
small airways disease, the expiratory SVC is generally higher than the FVC. 
This difference might, however, be due partly to the difficulty in maintaining 
a maximum expiratory effort for an extended time period without experiencing 
dizziness or light headedness.” 
 
 29 
 
 
“A spirometer, including the waterless, rolling seal type, and Stead-Wells water 
seal type is an instrument that directly measures the volume of air displaced or 
measures airflow by a flow-sensing device, such as a pneumotachometer or a 
 30 
 
tube containing a fixed resistance to flow. Today, most clinical pulmonary 
function testing laboratories use a microprocessor-driven pneumotachometer to 
measure air flow directly and then to mathematically derive volume.” 
 
 
 
“The frequently used water spirometer, consists of an inverted canister, or 
"bell," floating in a water-filled space between two concentrically arranged 
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cylinders. The space inside the inner drum, which is closed off from the 
atmosphere by the bell, is connected to tubing that extends to a mouthpiece into 
which the person breathes. As the person breathes in and out, gas enters and 
leaves the spirometer, and the bell then floats higher (during expiration) and 
lower (during inspiration). The top of the bell is connected by a pulley to a pen 
that writes on a rotating drum, thus tracing the person's breathing pattern.” 
“Types of Spirometers 
Volume 
 Bellows 
 Rolling seal 
 Water 
 Dry 
Flow Sensing (Pneumotach) 
 Fleisch 
 Screen 
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 Hot-wire 
 Turbine” 
 
 
The spirometer can measure only the lung volumes that the subject can 
exchange with it. As is the case with many pulmonary function tests, the subject 
must be conscious and cooperative and understand the instructions for 
performing the test. The VT, IRV, ERV, IC, and VC can all be measured with a 
spirometer (as can the forced expiratory volume in 1 second [FEV1], forced vital 
capacity [FVC], and forced expiratory flow [FEF25–75%]). The RV,  FRC, and the 
TLC cannot be determined with a spirometer because the subject cannot exhale 
the lungs completely. The gas in a spirometer is at ambient temperature, 
pressure, and water vapour saturation, and the volumes of gas collected in a 
spirometer must be converted to equivalent volumes in the body. Other kinds of 
spirometers include rolling seal and bellows spirometers. These spirometers are 
not water-filled and are more portable 
“A spirogram is a graphic representation of bulk air movement depicted as a 
volume-time tracing or as a flow-volume tracing. Values generated from a 
simple spirogram provide important graphic and numeric data regarding the 
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mechanical properties of the lungs, including airflow (forced expiratory volume 
in 1 second [FEV1] along with other timed volumes) and exhaled lung volume 
(FVC or SVC). The measurement is typically expressed in liters for volumes or 
in liters per second for flows and is corrected for body temperature and pressure 
of gas that is saturated with water vapor. Data from a spirogram provide 
important clues to help distinguish obstructive pulmonary disorders that 
typically reduce airflow, such as asthma and emphysema, from restrictive 
disorders that typically reduce total lung volumes, including pulmonary fibrosis 
and neuromuscular disease” 
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Forced Expiratory Volume in 1 Second 
“The FEV1 is the most widely used parameter to measure the mechanical 
properties of the lungs. In normal persons, the FEV1 accounts for the greatest 
part of the exhaled volume from a spirometric maneuver and reflects mechanical 
properties of the large and the medium-sized airways. In a normal flow-volume 
loop, the FEV1 occurs at about 75% to 85% of the FVC. This parameter is 
reduced in obstructive and restrictive disorders. In obstructive diseases, FEV1 is 
reduced disproportionately to the FVC, reducing the FEV1/FVC ratio below the 
lower limit of normal and indicates airflow limitation. In restrictive disorders, 
the FEV1, FVC, and total lung capacity are all reduced, and the FEV1/FVC ratio 
is normal or even elevated.” 
Forced Vital Capacity 
“ FVC is a measure of lung volume and is usually reduced in diseases that cause 
the lungs to be smaller. Such processes are generally termed restrictive and can 
include disorders of the lung parenchyma, such as pulmonary fibrosis, or of the 
bellows, including kyphoscoliosis, neuromuscular disease, and pleural effusion. 
However, a reduction in FVC is not always due to reduced total volumes and 
can occur in the setting of large lungs hyperinflated due to severe airflow 
obstruction and air trapping, as in emphysema. In this setting, the FVC is 
decreased due to reduced airflow, air trapping, and increased residual volume, a 
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phenomenon referred to as pseudorestriction. Reduced FVC can occur despite a 
normal or increased total lung volume. Therefore, FVC is not a reliable 
indicator of total lung capacity or restriction, especially in the setting of airflow 
obstruction. The overall accuracy of the FVC for restriction is about 60%” 
 
 
 
FEV1, forced expiratory volume in 1 second;  
LLN, lower limit of normal;  
TLC,total lung capacity;  
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VC,vitalcapacity.  
 
“Adapted from American Thoracic Society: Lung function testing: Selection of 
reference values and interpretative strategies. Am Rev Respir Dis 
1991;144:1202-1218”. 
 
Measurement of Lung Volumes Not Measurable with Spirometry 
The residual volume (RV), total lung capacity (TLC) and related volumes 
cannot be measured directly so special techniques are required to record these 
volumes. There are several accepted methods for determining these volumes, 
which are frequently referred to as 'static lung volumes'. These methods include 
helium dilution, nitrogen washout and body plethysmography  
The FRC is usually determined, and RV (which is equal to FRC minus ERV) 
and the TLC (which is equal to VC plus RV) are then calculated from volumes 
obtained by spirometry. 
Nitrogen-Washout Technique 
In the nitrogen-washout technique, the person breathes 100% oxygen through a 
one-way valve so that all the expired gas is collected. The concentration of 
nitrogen in the expired air is monitored with a nitrogen analyzer until it reaches 
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zero. At this point all the nitrogen is washed out of the person's lungs. The total 
volume of all the gas the person expired is determined, and this amount is 
multiplied by the percentage of nitrogen in the mixed expired air, which can be 
determined with the nitrogen analyzer. The total volume of nitrogen in the 
person's lungs at the beginning of the test can thus be determined. Nitrogen 
constitutes about 80% of the person's initial lung volume, and so multiplying the 
initial nitrogen volume by 1.25 gives the person's initial lung volume. If the test 
is begun at the” end of a normal expiration, “the volume determined is the FRC. 
Total Volume expired X %N2 = original volume of N2 in the lungs 
original volume of N2 in the lungs X 1.25 = original Lung Volume 
 
Helium Dilution Methods: 
Helium (He) is an inert, poorly soluble gas. The principle in helium dilution 
methods is that if a gas with known He concentration is breathed in, the He will 
be diluted by the He-free gas within the lungs. If the expired He concentration is 
monitored the volume of gas within the lungs can then be calculated from the 
dilution effect. 
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For example, if a known amount of a solute is dissolved in an unknown volume 
of solvent, and the concentration of the solute can be determined, then the 
volume of solvent can be calculated:   
Amount of solute (mg) = concentration of solute (mg/mL) X 
                                                                                    volume of solvent (mg) 
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In the helium-dilution technique, helium is dissolved in the gas in the lungs and 
its concentration is determined with a helium meter, allowing calculation of the 
lung volume. Helium is used for this test because it is not taken up by the 
pulmonary capillary blood and because it does not diffuse out of the blood, and 
so the total amount of helium does not change during the test. The person 
breathes in and out of a spirometer filled with a mixture of helium and oxygen. 
The helium concentration is monitored continuously with a helium meter until 
its concentration in the inspired air equals its concentration in the person's 
expired air. At this point, the concentration of helium is the same in the person's 
lungs as it is in the spirometer, and the test is stopped at the end of a normal  
expiration. 
The FRC can then be determined by the following formula (total amount of He 
before test = total amount of He at end of test):  
      ` 
That is, the total amount of helium in the system initially is equal to its initial 
fractional concentration (FHEi) times the initial volume of the spirometer (Vspi). 
This must be equal to the total amount of helium in the lungs and the spirometer 
at the end of the test, which is equal to the final (lower) fractional concentration 
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of helium (FHEf) times the final volume of the spirometer (Vspf) and the 
volume of the lungs at the end of the test (VLf). Since it may take several 
minutes for the helium concentration to equilibrate between the lungs and the 
spirometer, in practice, CO2 is absorbed from the system and oxygen is added to 
the spirometer at the rate at which it is used by the person. Both the nitrogen-
washout and helium-dilution methods can be used on unconscious patients. 
 
Body Plethysmography: 
A problem common to both the nitrogen-washout technique and the helium-
dilution technique is that neither can measure trapped gas because nitrogen 
trapped in alveoli supplied by closed airways cannot be washed out and because 
the helium cannot enter alveoli supplied by closed airways. Furthermore, if the 
patient's lungs have many alveoli served by airways with high resistance to 
airflow , it may take a very long time for all the nitrogen to wash out of the 
patient's lungs or for the inspired and expired helium concentrations to 
equilibrate. In such patients, measurements of the lung volumes with a body 
plethysmograph are much more accurate because they do include trapped gas. 
The body plethysmograph works on “Boyle's law, which states that for a closed 
container at a constant temperature, the pressure times the volume is constant.” 
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The body plethysmograph, an expensive piece of equipment, is shown 
schematically in Figure below:  
 
 
-The subject is seated in the small airtight chamber and breathes through the 
apparatus shown. By monitoring the subject's airflow with a pneumotachograph, 
the operator can briefly occlude the subject's airway at end expiration. As the 
subject makes an inspiratory effort against the closed airway, the pressure in the 
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chamber (Pbox) increases and the pressure at the subject's mouth (PM) decreases. 
The subject's functional residual capacity can then be calculated. 
 
Diffusing Capacity 
“Understanding gas diffusion through the lungs requires recognizing the basics 
of the gas exchange interface and of the various forces at work by which oxygen 
and carbon dioxide move by molecular diffusion. Diffusion is limited by the 
surface area in which diffusion occurs, capillary blood volume, hemoglobin 
concentration, and the properties of the lung parenchyma that separate the 
alveolar gas from the red blood cell with the capillary (alveolar-capillary 
membrane thickness and/or the presence of excess fluid in the alveoli)” 
“Because all lung volume is not exchanged, most gas exchange occurs as a 
function of diffusion independent of bulk flow” 
“The clinical test diffusing capacity of the lung most commonly uses carbon 
monoxide as the tracer gas for measurement because of its high affinity for 
binding to the hemoglobin molecule. This property allows a better measurement 
of pure diffusion, such that the movement of the carbon monoxide in essence 
only depends on the properties of the diffusion barrier and the amount of 
hemoglobin.” 
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“Diffusing capacity of the lung for carbon monoxide (DLCO) is the measure of 
carbon monoxide transfer. In Europe, it is often called the transfer factor of 
carbon monoxide,which describes the process more accurately 
A pattern of diffusing capacity reduced proportionate to airflow obstruction (a 
proportionate reduction in FEV1 and DLCO) is typical for emphysema. A DLCO 
is reduced proportionately to a reduction in total lung capacity in the context of 
restrictive abnormalities suggests a parenchymal process such as pulmonary 
fibrosis. An isolated or disproportionate reduction in diffusing capacity along 
with either normal or fairly well preserved mechanics suggests predominantly a 
pulmonary vascular process such as primary pulmonary hypertension or 
thromboembolic disease.” 
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Diabetes Mellitus 
“Diabetes mellitus is a chronic disorder characterized by hyperglycemia and the 
late development of vascular and neuropathic complications. Regardless of its 
cause, the disease is associated with a common hormonal defect— namely, 
insulin deficiency—that may be absolute or relative in the context of coexisting 
insulin resistance. The effect of insufficient insulin plays a primary role in the 
metabolic derangements linked to diabetes; hyperglycemia, in turn, plays an 
important role in disease-related complications.” 
 
Diabetes is the single most important metabolic disease which can affect nearly 
every organ in the body and is therfore widely  recognized as one of the leading 
causes of death and disability worldwide. 
 
Currently  more than 62 million Indians are diabetic. Nearly 1 million Indians 
die due to diabetes every year. These statistics have conferred the dubious title 
of DIABETES CAPITAL to our country. 
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Etiological Classification of Diabetes: 
The vast majority of  diabetes cases fall into two broad etiopathogenetic 
categories: 
1.” Type 1 diabetes mellitus (T1DM): Absolute deficiency of insulin secretion 
2. Type 2 diabetes mellitus (T2DM): Combination of insulin resistance and 
inadequate compensatory insulin secretory response (relative insulin 
deficiency). Diabetes can also develop secondary to other causes like genetic 
defects in beta cell function, genetic defects in insulin action and diseases of the 
exocrine pancreas or intake of certain drugs.” 
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DIAGNOSIS OF DIABETES MELLITUS 
“Diagnosis of diabetes is based upon plasma glucose levels. Three ways to 
diagnose diabetes are possible and each, in the absence of unequivocal 
hyperglycemia, must be confirmed, on a subsequent day. The 75 g oral glucose 
tolerance test (OGTT) is more sensitive and modestly more specific than fasting 
plasma glucose (FPG) in the diagnosis of diabetes, but is poorly reproducible. 
Because of its ease, patient acceptability and lower cost, measurement of FPG is 
the preferred diagnostic test. The use of the hemoglobin A1c (glycosylated 
hemoglobin or HbA1c) for the diagnosis of diabetes was previously not 
recommended due to lack of global standardization and uncertainty about 
diagnostic thresholds. Presently, because of a worldwide move towards a 
standardized assay and with increasing evidence about the prognostic 
significance of HbA1c, it is included as a diagnostic test in the 2011 American 
Diabetes Association (ADA) guidelines” 
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*In the absence of unequivocal hyperglycemia, the first three criteria should be 
confirmed by repeat testing on a different day. 
 
CONCEPT OF PREDIABETES 
 
The above Figure shows the Natural History of  Type 2 Diabetes and its 
evolution. 
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Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are the 
fore-runners of future T2DM (collectively termed as prediabetes). 
The significance of impaired fasting glycemia and IGT  
• Increased risk for cardiovascular/cerebrovascular diseases  
• Predictor of subsequent diabetes mellitus  
• Diabetic range values may be unmasked with stress 
 
Diagnosis of IFG and IGT based on International Diabetes Federation criteria 
 
 
 
CONCEPT OF “THE METABOLIC SYNDROME” 
The metabolic syndrome also referred to as syndrome X or insulin resistance 
syndrome refers to a cluster of cardiovascular disease risk factors and metabolic 
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alterations associated with excess body fat. Even though there are different 
definitions the following are central to the diagnosis abdominal obesity, 
dyslipidemia, hypertension and glucose intolerance or diabetes.  
Insulin resistance and accompanying hyperinsulinemia is said to play a central 
role in the pathogenesis of the syndrome with a casual relationship to 
hypertension.This may be due to the effects of insulin in the periphery on 
vasculature as well as a central action leading to stimulation of sympathetic 
activity and in turn the renin-angiotensin-aldosterone system. 
 
“Despite the importance of the metabolic syndrome as a risk marker, there 
remains disagreement regarding the best way to define it. The current scientific 
statement attempts to clarify the definition of metabolic syndrome and identifies 
possible future refinements to this definition.” 
“The most significant controversy regarding the definition of the metabolic 
syndrome has been the inclusion of abdominal obesity. It has been required in 
some recommendations to diagnose the metabolic syndrome, whereas it has 
served as a nonintegral variable in the diagnosis in other algorithms.” 
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Different definitions of metabolic syndrome 
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Criteria for clinical diagnosis of the metabolic syndrome. 
 
SCREENING FOR DIABETES 
The following are the ADA guidelines to select asymptomatic adult individuals 
who will need testing for prediabetes and diabetes 
“Testing should be considered in all adults who are overweight [body mass 
index (BMI) ≥ 25 kg/m2 ] and have additional risk factors:  
A. Physical inactivity  
B. First-degree relative with diabetes  
C. Members of a high-risk ethnic population (e.g. African American, Latino, 
Native American, Asian American, Pacific Islander)  
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D. Women who delivered a baby weighing >4 kg or were diagnosed with 
gestational diabetes mellitus (GDM)  
E. Hypertension (≥140/90 mm Hg or on therapy for hypertension)  
F. HDL cholesterol level 250 mg/dL (2.82 mmol/L)  
G. Women with polycystic ovarian syndrome (PCOS)  
H. IGT or IFG on previous testing  
I. Other clinical conditions associated with insulin resistance (e.g. severe 
obesity, acanthosis nigricans)  
J. History of cardiovascular disease.  
2. In the absence of the above criteria, testing for prediabetes and diabetes 
should begin at the age of 45 years.  
3. If results are normal, testing should be repeated at least at 3 year intervals, 
with consideration of more frequent testing depending on initial results and risk 
status.” 
 
GLYCOSYLATED HEMOGLOBIN 
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Glycation refers to nonenzymatic addition of a sugar residue to an amino group 
of a protein. Hemoglobin, plasma proteins, membrane proteins, lens protein, etc. 
may undergo glycosylation. HbA1c forms the major fraction (80%). In HbA1C, 
the “N-terminal valine residue of each beta chain gets glycated. HbA1c gives a 
retrospective index of integrated plasma glucose values over a 6–8 weeks period 
and is not subject to wide fluctuations” in plasma glucose levels. 
HbA1c serves as a reliable indicator of diabetes control during the past 90 days, 
effectiveness of treatment and risk of development of acute or long-term 
complications. Hence HbA1c should be performed routinely in all patients with 
diabetes, to assess the degree of glycaemic control at initial visit and then as a 
part of continuing visits every three months to assess metabolic control.  
 
Normal HbA1c values and interpretation 
• Normal nondiabetic range: 4.5–5.8%  
• Serious risk of hypoglycemia: < 4.5  
• Diabetic range: > 6.5%  
• Prediabetic range: 5.8–6.5% 
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There are some conditions which may lead to a false elevation or reduction in 
HbA1c levels. Hemoglobinopathies like thalassemia, hereditary persistence of 
fetal hemoglobin, a low hemoglobin level per se (<7.0 g/dL) and uremia are 
known to cause altered levels of HbA1c. 
 
Approximate correlation between glycosylated hemoglobin (HbA1c) and mean 
plasma glucose levels: 
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Follow-up of patients and frequency of testing 
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Diabetes and its Complications 
Consequences of disturbed metabolism in diabetes: 
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“The microvascular complications of both type 1 and type 2 DM result 
from chronic hyperglycemia. Evidence implicating a 
causative role for chronic hyperglycemia in the development of macrovascular 
complications is less conclusive. CHD events and mortality 
rate are two to four times greater in patients with type 2 DM and correlate with 
fasting and postprandial plasma glucose levels as well the hemoglobin A1c 
(HbA1c). Other factors such as dyslipidemia and hypertension also play 
important roles in macrovascular complications.” 
 
 59 
 
 
 
 
 60 
 
MECHANISMS OF COMPLICATIONS 
“Although chronic hyperglycemia is an important etiologic factor leading to 
complications of DM, the mechanism(s) by which it leads to 
such diverse cellular and organ dysfunction is unknown. An emerging 
hypothesis is that hyperglycemia leads to epigenetic changes that influence gene 
expression in affected cells.” 
Some theories include: 
(1) “Increased intracellular glucose leads to the formation 
of advanced glycosylation end products, which bind to a cell surface 
receptor, via the nonenzymatic glycosylation of intra- and extracellular 
proteins, leading to cross-linking of proteins, accelerated atherosclerosis, 
glomerular dysfunction, endothelial dysfunction, and altered 
extracellular matrix composition” 
(2) “Hyperglycemia increases glucose  metabolism via the sorbitol 
pathway related to the enzyme aldose reductase. However, testing of this theory 
in humans, using aldose reductase inhibitors, has not demonstrated beneficial 
effects.” 
(3) “Hyperglycemia increases the formation of diacylglycerol, leading to 
activation of protein kinase C, which alters the transcription of genes for 
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fibronectin, type IV collagen, contractile proteins, and extracellular matrix 
proteins in endothelial cells and neurons.”  
(4) “Hyperglycemia increases the flux through the hexosamine pathway, which 
generates fructose-6-phosphate, a substrate for O-linked glycosylation and 
proteoglycan production, leading to altered function by glycosylation of proteins 
such as endothelial nitric oxide synthase or by changes in gene expression of 
transforming growth factor β (TGF-β) or plasminogen activator inhibitor-1.” 
 
Diabetic Retinopathy: 
Diabetic retinopathy is the most common cause of legal blindness between the 
ages of 20 and 70 years. Blindness usually results from non-resolving vitreous 
hemorrhage, tractional retinal detachment or diabetic macular edema. However, 
the 5-year risk of severe visual loss can be reduced if a person with proliferative 
DR undergoes laser photocoagulation. DR is often asymptomatic in its most 
treatable stages; hence early detection through regularly scheduled ocular 
examination is critical. 
Risk Factors: 
• Duration of diabetes – Most important factor – Longer the duration higher the 
incidence (after 10 years of DM, incidence of retinopathy is 50% in patients less 
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than 30 years of age and 90% in patients more than 30 years) – Rare before 
puberty. 
• Poor control of diabetes – Worsens the progression – Tight control does not 
guarantee prevention, but delays the onset and slows progression.  
• Pregnancy – Associated with rapid progression of pre-existent retinopathy 
especially if prepregnancy control was poor – Postpartum reversal of 
retinopathy may occur – It is rare for women without retinopathy to develop it 
during pregnancy – De novo gestational diabetes has no risk of retinopathy.  
• Hypertension is associated with worsening  
• Nephropathy – Associated with worsening – Treatment as with renal 
transplantation leads to improvement.  
• Obesity  
• Hyperlipidemia  
• Smoking 
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PATHOGENESIS OF DIABETIC RETINOPATHY: 
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Algorithm for management of retinopathy: 
 
 
 
DIABETIC NEPHROPATHY 
“Diabetic nephropathy is one of the leading causes of chronic renal failure and 
end stage renal disease. this is due to the increasing prevalence of type 2 
diabetes, longer life span of diabetic patients and improved therapeutic options.” 
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   “Diabetic retinopathy is clinically defined as the presence of persistent 
proteinuria of mre than 500 mg/day in a diabetic patient with concomitant 
evidence of diabetic retinopathy and hypertension ,in the absence of other 
kidney or renal tract disease.” 
Diabetic patients are 17 times more prone to develop nephropathy than the 
general population.the peak onset of DN in type 1 diabetes is between 10-15 
years after onset of disease. 
 
Stages of diabetic nephropathy 
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Revised KDIGO CKD classification based on GFR and albuminuria and risk 
stratification: 
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Algorithm for management of diabetic nephropathy: 
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DIABETIC NEUROPATHY: 
Diabetic neuropathy is a heterogenous condition that encompasses a wide range 
of peripheral nerve dysfunction and whole development might be attributed to 
diabetes per se or to factors associated in the disease  . It is the most common 
and most troublesome of all diabetic complications. 
Diabetic neuropathy is defined as the presence of symptoms and signs of 
peripheral nerve dysfunction in people with diabetes after exclusion of other 
causes the neuropathic dysfunction is manifested in the somatic and autonomic 
nervous system. 
CLASSIFICATION OF DIABETIC NEUROPATHY: 
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PATHOGENESIS OF DIABETIC NEUROPATHY: 
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Algorithm for management of diabetic peripheral neuropathy 
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LUNG INVOLVEMENT IN DIABETES: 
Despite advancements in understanding the pathogenesis of diabetes and the 
complications, the pathology of lung involvement is not well established. The   
PFT might show a restrictive pattern. The probable mechanisms explained are 
due to the advanced glycation of end products (AGE’s). first due to the pro 
inflammatory effect of AGE’s . Second one is functional alteration of lung 
connection tissue by AGE’s.The other proposed mechanisms are micro vascular 
involvement lead to changes in lung parenchyma. Due to endothelial 
dysfunction vasodilation does not occur. Insulin resistance may also play role in 
lung dysfunction. Neuropathy of thoracic nerves leading to respiratory muscle 
abnormality may have a role. 
        With these proposed mechanisms it is clear that   pulmonary involvement 
is similar to other micro vascular complications of diabetes and may co exist 
with other micro and macro vascular complications. 
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METHODOLOGY 
One hundred diabetic patients previously diagnosed, belonging to either sex 
attending / admitting to OPD/wards of Govt. Rajaji hospital, Madurai 
medical College  Madurai , will be studied. 
Patients will be classified into three groups A, B, C depending on the 
duration of diabetes. 
Group A consists of diabetes with duration of up to 3 years. 
Group B consists of diabetes with duration of 3to 5 years. 
Group C consists of diabetes with duration of 5 to 7 years. 
SOURCE OF DATA 
“Patients with diabetes mellitus attending OPD in Department of diabetology  
and admitted in department of general medicine Of Government Rajaji Hospital, 
Madurai during the study period of  june 2016 to august  2016.” 
SAMPLE SIZE 
100 cases 
DURATION OF STUDY 
June 2016 to August 2016 
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INCLUSION CRITERIA 
    “Previously diagnosed Type 2 Diabetic patients for less than 7 
years,between age 40-60 years,with regular follow up. One hundred  age and 
sex matched non diabetic were included as the other group. Diabetes was ruled 
out in non diabetic group with fasting and 2-hr post prandial blood glucose 
measurement.” 
                                         EXCLUSION CRITERIA 
  Smokers, 
 patients with previous/present cardio respiratory diseases 
 h/o occupational exposure 
 Persons with physical disabilities 
 Obese (BMI>30) 
 Neuromuscular diseases 
METHOD OF COLLECTION OF DATA 
 
“Diabetic patients of different durations were selected carefully using criteria 
laid down. Their written consent was taken. The history was elicited. Age, 
 75 
 
height, weight were recorded. Thorough clinical examination was carried 
out. The  performance of the pulmonary function tests was demonstrated.” 
“Patients were made to undergo pulmonary function tests using Medspiror, 
for 3 times at every 15 minutes interval and best of 3readings was taken. 
The Forced Vital Capacity (FVC), Forced Expiratory Volume at the end of 
one second (FEV1), Peak Expiratory Flow Rate (PEFR),FEV1/ FVC ratio 
were recorded.” 
“Diabetes mellitus was ruled out in non diabetic group by fasting and post 
prandial blood glucose was analysed by GOD-PAP(glucose oxidase-phenol 4-
aminophenazone peroxidase)method.” 
Other relevant investigations are done 
 ECG in all leads 
 Echocardiogram 
 Fasting and 2 hr blood sugar 
 Chest X RAY 
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STATISTICAL ANALYSIS 
      Statistical analysis was done by using percentages, mean values, standard 
deviation, chi-square test, t-test and proportion test. A p-value <0.05 level was 
considered statistically significant and a p-value >0.05 was considered as not 
statistically significant. 
 
 
 
 
SEX DISTRIBUTION OF CASES & CONTROLS 
 
 
 
 
 
 
 
Sex CASE CONTROL 
Male 60 60 
Female 40 40 
Total 100 100 
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Of  the total 100 patients 60 are males and 40 females. Among the controls 60 
males and 40 females were chosen. 
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AGE  WISE DISTRIBUTION OF CASES 
 
 
 
 
 
Total 100 
 
In age distribution most of our patients(28%) were in age group of 55-60yrs- 28 
patients. Least number of patients(22%) were in 40-45years group-22 
This is suggestive that most of the patients have been diagnosed later.` 
 
AGE Total 
40 - 45  22 
45 - 50   
24 
50 - 55  
26 
55 - 60  
28 
 79 
 
 
 
 
 
AGEWISE DISTRIBUTION OF PATIENTS 
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CLASSIFICATION OF DIABETIC PATIENTS INTO THREE GROUPS 
BASED ON DUARTION OF DIABETES 
 
 
 
 
 
 
The diabetic patients are classified into three groups A,B,C  based on duration 
of diabetes <3.3-<5,>5 years respectively  for the purpose of conducting the 
study. 
Among the three groups group A has maximum  number of patients and group 
B having least number of patients. 
 
 
 
DURATION OF 
DIABETES IN 
YEARS GROUP 
No.of cases 
 
<3 A 40 
 3-<5 B 28 
 
>5 C 32 
 
 Total 100 
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TABLE OF  COMPARISON OF DURATION OF DIABETES WITH SEX 
DISTRIBUTION 
 
 
No.of 
cases 
  
Duration 
of DM Male Female 
Total 
< 3 40   < 3 24 16 40 
 3 to <5 28    3 to <5 16 12 28 
  5 - 7   32     5 - 7   20 12 32 
Total 100   Total 60 40 100 
 
 
Among the patients 60%(60) are males and 40%(40) are females .  
Even among the three groups in all the groups males are predominant than 
females.  
Thus males are the predominant population of our study.  
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COMPARISON OF DIABETIC PATIENTS BASED ON THEIR 
TREATMENT(INSULIN OR OHA) 
 
 
 
 
  TREATMENT 
DM INSULIN  OHA 
< 3 6 34 
 3 to <5 10 18 
  5 - 7   8 24 
Total 24 76 
 
 
Among the patients most of our patients are OHA treated (76%) when compared 
to INSULIN treated(24%) 
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COMPARISON OF FBS & PPBS AMONG CASES AND CONTROLS 
 
CASE CONTROL 
FBS 131.95 85.38 
PPBS 212.7 122.85 
 
 
 
A comparison among the patients and controls were made by using FBS,PPBS 
was made,which showed our diabetics had sugar values in the range of diabetes 
as mentioned by American diabetes association. And our controls were healthy 
individuals with no abnormality in blood sugar values. 
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COMPARISON OF FEV1 & FVC AMONG CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
After comparing the FEV1 & FVC among the study and controls it was found 
that FEV1 was 2.496 when compared with 3.014 with controls for which the p 
value was <0.001 which is significant, FVC was 3.161among cases when 
compared with controls 3.79 which shows that there is reduction in FEV1 and 
FVC among diabetics when compared with non diabetics which was statistically 
significant. 
 
CASE CONTROL 
FEV1 2.496 3.014 
  FVC 3.161 3.79 
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COMPARISON  OF FBS,PPBS,FEV1,FVC,FEV1/FVC,PEF AMONG 
CASES &  CONTROLS 
 
 
Comparison 
CASE CONTROL 
P'Value 
Mean  SD Mean  SD 
FBS 131.95 14.712 85.38 8.098 <0.001 
PPBS 212.7 34.735 122.85 15.085 <0.001 
FEV1 2.496 0.476 3.014 0.431 <0.001 
  FVC 3.161 0.568 3.79 0.603 <0.001 
FEV1/FVC % 78.901 3.935 79.984 5.43 0.108 
PEFR 486.74 73.569 535 72.744 <0.001 
 
 
 
When a final comparison is made with all the pulmonary function tests and it is 
observed that FEV1,FVC,PEFR had significant reduction among diabetic 
patients and this was found to be statistically  significant (p<0.001) . but 
FEV1/FVC  was not significant (p=0.108) which needs to evaluated further . 
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COMPARISON OF FBS,PPBS,FEV1,FVC,FEV1/FVC,PEF AMONG 
DIFFERENT GROUPS OF DIABETIC PATIENTS 
 
 
Duration of 
DM in years 
 <3   3 to <5   5 - 7     
P 
 Mean  SD Mean  SD Mean  SD 
 FBS 122.80 11.43 129.00 10.93 145.97 10.21 <0.001 Sig 
PPBS 198.88 26.22 216.79 45.51 226.41 27.00 0.002 Sig 
FEV1 2.65 0.48 2.65 0.39 2.17 0.39 <0.001 Sig 
  FVC 3.33 0.568 3.329 0.474 2.802 0.481 <0.001 Sig 
FEV1/FVC % 
79.531 4.174 79.563 3.789 77.533 3.494 0.057 
Not 
Sig 
PEF 509.9 75.681 480.679 75.683 463.094 61.543 0.022 Sig 
 
 
On observing all the pulmonary function tests among three groups and it is 
observed that FEV1,FVC,PEFR had significant reduction among diabetic 
patients and this was found to be statistically  significant (p<0.001). . but 
FEV1/FVC  was not significant (p=0.057). 
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DISCUSSION 
Diabetes is a multisystem disease . involvement of cardiac,renal,ocular systems 
are more extensively studied when compared to lung involvement. The cause of 
lung function has not been studied. There are no detailed proposed mechanisms 
for it . 
       Possible mechanisms are microvascular changes in lung tissue will lead to 
impairement in pulmonary functions. Few studies have shown that T2DM with 
microangiopathies show reduced diffusion capacity for carbon monoxide 
(DLCO).The study further suggested that hyperglycaemia and dyslipidaemia 
might have a contributory role in its pathogenesis. 
        In this study we found that diabetics had decreased lung volumes compared 
to normoglycemic subjects. FVC, FEV1,FVC/FEV1 & PEFR were 
statististically significantly lower in diabetic patients than in normal controls 
(p<0.05): 
      In the present study, two hundred patients with type 2 diabetes mellitus were 
taken, of which 100 patients are diabetic and 100 patients non diabetic. 
Pulmonary function tests was compared between these two groups, along with 
comparison of other parameters. 
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 On analysing results, patients had significant impairment in FEV1 (2.496 in 
patients when compared with 3.014 with controls) for which the p value was 
<0.001 which is statistically significant. 
This concludes have a significant reduction in the FEV1 when compared with 
the controls. 
Also FVC was 3.161among cases when compared with controls 3.79 which also 
showed a statistically significant reduction. 
  Our results showed a similar results with schanek et al,ljubic et al. 
Similar to our study Gregory L. Kinney et al have observed a moderate 
reduction in FVC,FEV1 and diffusing capacity for carbon monoxide of the lung 
in patients with type 1 and type 2 diabetes. 
YehHC et al have suggested that pulmonary function test in middle aged non 
diabetic adult showed a restrictive pattern of lung pathology which is predictive 
of subsequent type 2 diabetes. 
David et al studied 495  diabetic patients and recorded baseline values. A subset 
of 125 patients were studied after 7 years, who showed a significant reduction in 
the  FEV1,FVC,PEFR . 
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 Irfan et al studied 64 diabetic and 64 non diabetic patients and showed that 
diabetic patients had reductions in FEV1,FVC when compared with non diabetic 
controls. This result concurred with our result. 
 
The FEV1/FVC % in our study was lower than normal and was found to have 
restrictive pattern. This is in concordance Boulbou et al ,Sultan et al, Sreeja et 
al, Fimognari et al, and Nakagima et al,   
Studies of klein OL stated diabetics have reduced FVC more consistent than 
reduced FEV1 and our study had given similar results. 
PEFR was also reduced in our study which was similar to Sreeja et al. 
 Among the groups A,B,C the pattern of restrictive PFT  is more prominent as 
the duration advances FEV1(A=2.65 B=2.65 C=2.17) , FVC( A=3.33 B=3.33 
=3.17)  PEFR (A=509 B=480  C=463). So which gives the impression that 
restriction is more prominent as the disease duration advances.  
 
Despite the reduction in FEV1&FVC, FEV1/FVC%(A=79.53 B=79.56 
C=77.53)  ratio declines but which is more than the predicted value. Davis et al 
had reported that FEV1% declines approximately about 1.5 % for each year of 
diabetes. 
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Kanya Kumari et al studied 125 patients and showed that type 2 diabetes 
patients have a restrictive pattern of PFT.  And the restriction is more prominent 
as the duration of diabetes is prolonged which concurs with our study. 
 
Anuradha et al, Kapoor et al also had similar results in their results. 
Also patients had higher mean FBS(131),PPBS(212) than healthy controls 
FBS(85),PPBS(122). Interestingly patients with higher FBS,PPBS  had more 
decrease in PFT values when compared with lower FBS,PPBS which was also 
statistically significant. 
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SUMMARY 
 Mean FEV1 in our study is 2.496 litres/min which is reduced 
significantly than control (p<0.001) 
 Mean FVC in our study is 3.161 which is reduced significantly 
(p<0.001) 
 There is a restrictive pattern in diabetics when compared with the non 
diabetic controls of same age. 
 FEV1,FVC,FEV1/FVC,PEFR are low in type -2 diabetic patients 
when compared to non diabetic patients. 
 FEV1,FVC,PEFR reductions are statistically significant. 
 FEV1/FVC% reduction is not statistically significant. 
 The reductions of FEV1,FVC,PEFR are more as the duration of 
diabetes advances and these reductions are statistically 
significant(p<0.001) 
 The reduction in  FEV1,FVC,PEFR are inversely co related to 
glycaemic control. Poor glycaemic control results in increased 
impairment of  these parameters. 
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LIMITATIONS 
 It is a single centre study so results are needed to be evaluated 
further. 
 DLCO is not studied in this study,which is also an iimportant 
parameter in PFT 
 Type 1 diabetics are not included. 
 Period of study is short. 
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CONCLUSIONS 
 
 Type-2 diabetic patients have reduced FEV1,FVC,PEFR when 
compared with non diabetics of same age .  
 Type 2 diabetic patients have a restrictive pattern of  pulmonary 
function tests even in the absence of any symptoms. 
 This restrictive pattern is more prominent as the duration of diabetes 
is increased. 
 Thus spirometry can be used as a simple investigation to study the 
pulmonary morbidity among the diabetics and to  plan for an effective 
aggressive strategy in management of  diabetes.  
 Periodic monitoring of lung functions is nessacary in diabetics as 
spirometry is a cost effective, non-invasive tool. 
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PROFORMA: 
Name: 
Age / Sex: 
IP no: 
Occupation: 
Presenting complaints: 
 
 
Past History: 
H/o DM, HT, CVD,CAD,DRUG INTAKE, Thyroid disorders, 
malignancies pulmonary or extra pulmonary tuberculosis , CLD, COPD. 
Duration of diabetes-  (completed years) 
Personal history 
smoker/ nonsmoker 
alcoholic/ non alcoholic 
Family H/o COPD,Bronchial asthma 
Treatment history  
Oral hypoglycemic agents/ insulin 
Clinical Examination: 
 
 
General Examination 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,  
 
 
 
 
Vitals: 
PR 
BP 
RR 
SpO2 
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
Laboratory investigations: 
Complete hemogram 
Renal function test  
Liver function test  
Sputum AFB, gram stain & culture 
Chest x-ray PA view 
Urine routine 
FBS,PPBS 
 
 
PULMONARY FUNCTION TESTS: 
FEV1 
FVC 
FEV1/FVC% 
PEFR 
 
TREATMENT: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVATIONS 
 
FBS            FASTING BLOOD SUGAR 
PPBS          POST PRANDIAL BLOOD SUGAR 
FEV1          FORCED EXPIRATORY VOLUME IN 1 SECOND 
FVC            FORCED VITAL CAPACITY 
PEFR          PEAK EXPIRATORY FLOW RATE 
OHA           ORAL HYPOGLYCEMIC AGENTS 
TLC            TOTAL LUNG CAPACITY;  
VC              VITAL CAPACITY.  
RV              RESIDUAL VOLUME 
FRC            FUNCTIONAL RESIDUAL CAPACITY 
IC                INSPIRATORY CAPACITY 
EC               EXPIRATOY CAPACITY 
 
 
 
 
  
          CONTROL       
S.NO AGE sex FBS PPBS FEV1   FVC FEV1/FVC PEF 
1 40 male 94 130 3.66 4.46 82.06 620 
2 42 male 88 118 3.62 4.62 78.35 616 
3 41 male 85 106 3.64 4.59 79.30 618 
4 44 male 91 104 3.57 4.42 80.77 614 
5 43 male 93 116 3.58 4.43 80.81 615 
6 45 male 76 118 3.54 4.39 80.64 613 
7 47 male 88 128 3.47 4.12 84.22 609 
8 48 male 75 110 3.44 4.22 81.52 607 
9 47 male 82 130 3.47 4.35 79.77 610 
10 49 male 80 115 3.35 4.23 79.20 605 
11 49 male 84 128 3.34 4.19 79.71 604 
12 47 male 83 135 3.45 4.36 79.13 609 
13 50 male 82 129 3.37 4.21 80.05 602 
14 53 male 96 136 3.35 4.2 79.76 595 
15 55 female 91 130 2.35 2.56 91.80 442 
16 51 female 92 129 2.45 3.56 68.82 444 
17 52 female 90 114 2.42 2.65 91.32 451 
18 53 female 80 136 2.4 2.72 88.24 450 
19 51 female 81 136 2.45 2.72 90.07 451 
20 55 male 70 120 3.23 4.21 76.72 442 
21 53 male 71 99 3.3 4.12 80.10 448 
22 55 male 76 100 3.23 4.22 76.54 442 
23 54 male 95 125 3.22 4.05 79.51 591 
24 54 male 88 128 3.21 4.21 76.25 590 
25 55 female 82 134 2.35 2.7 87.04 443 
26 50 male 84 130 3.37 4.31 78.19 603 
27 59 male 86 120 3.08 4.1 75.12 574 
28 58 male 94 138 3.11 4.12 75.49 578 
29 59 male 99 136 3.06 4.1 74.63 576 
30 47 female 95 135 2.44 2.7 90.37 460 
31 59 male 92 128 3.08 4.12 74.76 577 
32 46 female 94 130 2.49 3.52 70.74 459 
33 48 female 97 135 2.54 3.36 75.60 457 
34 58 male 98 128 3.11 4.11 75.67 536 
35 57 male 95 129 3.14 4 78.50 580 
36 48 female 96 18 2.57 3.39 75.81 609 
37 46 female 91 130 2.6 3.5 74.29 460 
38 59 male 88 112 3.06 4.09 74.82 576 
39 59 male 84 127 3.05 3.96 77.02 575 
40 56 male 86 120 3.26 4.25 76.71 590 
41 40 female 82 135 2.72 3.46 78.61 469 
42 59 female 83 136 2.25 3 75.00 434 
43 41 female 81 130 2.71 3.2 84.69 466 
44 58 female 89 140 2.26 2.96 76.35 436 
45 42 female 87 125 2.7 3.62 74.59 464 
46 57 female 74 118 2.31 2.56 90.23 439 
47 43 female 76 114 2.66 3.39 78.47 465 
48 56 female 75 100 2.32 2.9 80.00 440 
49 45 female 81 120 2.62 3.54 74.01 463 
50 58 male 86 117 2.27 2.99 75.92 578 
51 45 male 79 104 3.54 4.4 80.45 613 
52 40 female 83 131 2.73 3.6 75.83 467 
53 44 male 70 121 3.52 4.45 79.10 615 
54 41 female 79 124 2.69 3.45 77.97 465 
55 43 male 88 122 3.6 4.62 77.92 615 
56 42 female 91 129 2.67 3.32 80.42 463 
57 44 male 94 138 3.51 4.29 81.82 610 
58 43 female 96 135 2.67 3.39 78.76 464 
59 45 male 81 125 3.53 4.41 80.05 613 
60 45 female 72 135 2.63 3.32 79.22 463 
61 41 male 86 119 3.65 4.45 82.02 619 
62 50 male 75 105 3.39 4.12 82.28 603 
63 46 female 99 139 2.49 3.41 73.02 459 
64 49 male 92 129 3.35 4.09 81.91 605 
65 47 female 78 100 2.46 2.56 96.09 459 
66 48 male 84 130 3.44 4.21 81.71 603 
67 48 female 83 120 2.53 3.42 73.98 459 
68 47 male 91 115 3.46 4.16 83.17 610 
69 49 female 72 105 2.49 3.35 74.33 456 
70 46 male 77 120 3.49 4.26 81.92 610 
71 48 female 76 115 2.41 2.59 93.05 458 
72 47 male 95 129 3.46 4.2 82.38 609 
73 51 male 91 130 3.35 4.12 81.31 600 
74 52 female 98 136 2.42 2.56 94.53 451 
75 52 male 87 134 3.33 4.12 80.83 597 
76 54 female 86 125 2.33 2.56 91.02 446 
77 55 male 84 120 3.23 4.12 78.40 588 
78 53 female 95 135 3.3 4.12 80.10 448 
79 51 male 76 114 3.36 4.1 81.95 600 
80 52 female 77 112 2.42 2.56 94.53 451 
81 52 male 71 111 3.33 4.2 79.29 597 
82 54 female 96 136 2.37 2.96 80.07 444 
83 55 male 94 139 3.23 4.05 79.75 589 
84 51 male 96 136 3.36 4.21 79.81 599 
85 53 female 93 124 2.41 2.54 94.88 446 
86 55 male 82 122 3.23 3.96 81.57 587 
87 56 female 88 125 3.2 4.2 76.19 441 
88 57 female 84 121 3.16 4.09 77.26 439 
89 58 female 86 124 3.13 4.05 77.28 436 
90 60 female 65 129 3.06 4 76.50 431 
91 56 male 84 135 3.21 4.12 77.91 585 
92 56 male 95 140 3.3 4.12 80.10 584 
93 57 male 92 130 3.15 4.09 77.02 579 
94 57 male 76 103 3.16 4.12 76.70 580 
95 58 male 69 124 3.1 4.12 75.24 577 
96 58 male 84 110 3.09 3.96 78.03 579 
97 59 male 75 100 3.07 4.1 74.88 576 
98 59 male 84 120 3.05 3.98 76.63 571 
99 60 male 89 132 3.04 3.96 76.77 572 
100 60 male 94 123 3.05 4.06 75.12 574 
 
 
 
 
 
          
CAS
E             
S.N
O 
AG
E sex 
Duration of 
DM 
grou
p FBS 
PPB
S 
FEV
1 
  
FVC 
FEV1/FV
C PEF 
TREATME
NT 
1 40 male 1 A 104 165 3.36 3.96 84.85 590 INSULIN  
2 42 male 2 A 112 185 3.26 3.99 81.70 583 OHA 
3 41 male 1 A 125 199 3.35 3.59 93.31 588 INSULIN  
4 44 male 2 A 116 155 3.21 4.02 79.85 579 OHA 
5 43 male 1 A 120 187 3.3 4.12 80.10 584 OHA 
6 45 male 1 A 125 199 3.24 4.08 79.41 585 OHA 
7 47 male 2 A 136 212 3.16 4.26 74.18 575 OHA 
8 48 male 2 A 133 222 3.12 4.02 77.61 572 OHA 
9 47 male 1 A 125 200 3.15 3.96 79.55 579 INSULIN  
10 49 male 2 A 138 240 3.03 3.78 80.16 570 OHA 
11 49 male 1 A 139 210 3.08 3.85 80.00 575 OHA 
12 47 male 2 A 126 188 3.12 3.95 78.99 574 INSULIN  
13 50 male 4 B 145 255 2.72 3.4 80.00 548 OHA 
14 53 male 4 B 135 198 2.61 3.36 77.68 540 OHA 
15 55 
femal
e 1 A 140 177 2.05 2.54 80.71 412 INSULIN  
16 51 
femal
e 1 A 128 195 2.15 2.62 82.06 421 OHA 
17 52 
femal
e 2 A 130 210 2.07 2.45 84.49 414 OHA 
18 53 
femal
e 2 A 132 200 2.05 2.5 82.00 413 OHA 
19 51 
femal
e 2 A 140 231 2.09 2.9 72.07 416 OHA 
20 55 male 4 B 138 210 2.88 3.65 78.90 387 OHA 
21 53 male 4 B 136 236 2.95 3.45 85.51 540 OHA 
22 55 male 3 B 140 289 2.88 3.66 78.69 538 OHA 
23 54 male 3 B 133 298 2.92 3.49 83.67 541 INSULIN  
24 54 male 3 B 136 312 2.92 3.42 85.38 541 OHA 
25 55 
femal
e 2 A 128 200 3.05 3.76 81.12 407 OHA 
26 50 male 3 B 132 165 3.02 3.85 78.44 552 OHA 
27 59 male 7 C 144 254 2.42 3.02 80.13 505 OHA 
28 58 male 6 C 140 203 2.47 3.35 73.73 508 OHA 
29 59 male 6 C 142 266 2.42 3.11 77.81 504 OHA 
30 47 
femal
e 1 A 124 188 2.34 2.95 79.32 430 OHA 
31 59 male 5 C 135 250 2.43 2.98 81.54 515 OHA 
32 46 
femal
e 2 A 130 199 2.3 2.86 80.42 575 OHA 
33 48 
femal
e 3 B 130 210 2.18 2.66 81.95 407 OHA 
34 58 male 6 C 135 165 2.48 3.15 78.73 508 INSULIN  
35 57 male 6 C 140 200 2.47 2.99 82.61 510 OHA 
36 48 
femal
e 4 B 120 185 2.18 2.85 76.49 402 INSULIN  
37 46 
femal
e 3 B 112 174 2.25 2.85 78.95 414 INSULIN  
38 59 male 7 C 145 220 1.68 2.11 79.62 500 OHA 
39 59 male 7 C 140 210 1.69 2.15 78.60 500 OHA 
40 56 male 7 C 150 265 1.66 2.15 77.21 515 OHA 
41 40 
femal
e 4 B 125 186 2.37 2.92 81.16 419 INSULIN  
42 59 
femal
e 3 B 120 188 2.63 3.28 80.18 383 OHA 
43 41 
femal
e 4 B 130 200 2.34 2.87 81.53 410 INSULIN  
44 58 
femal
e 5 C 135 210 1.62 2.09 77.51 371 OHA 
45 42 
femal
e 6 C 140 230 2.02 2.64 76.52 401 INSULIN  
46 57 
femal
e 7 C 142 245 1.64 2.11 77.73 372 OHA 
47 43 
femal
e 5 C 132 205 2.01 2.59 77.61 399 OHA 
48 56 
femal
e 7 C 146 210 1.67 2.12 78.77 370 OHA 
49 45 
femal
e 6 C 150 225 2.03 2.46 82.52 402 OHA 
50 58 male 7 C 135 215 2.38 3.2 74.38 508 OHA 
51 45 male 1 A 100 166 2.32 2.9 80.00 585 OHA 
52 40 
femal
e 2 A 110 175 2.42 3.02 80.13 436 OHA 
53 44 male 2 A 115 180 3.25 4.08 79.66 425 OHA 
54 41 
femal
e 2 A 112 195 2.39 3.26 73.31 430 INSULIN  
55 43 male 3 B 90 150 3.25 4.13 78.69 564 OHA 
56 42 
femal
e 2 A 124 175 2.39 3.36 71.13 430 OHA 
57 44 male 4 B 115 175 3.16 4 79.00 559 OHA 
58 43 
femal
e 1 A 120 195 2.37 3.12 75.96 430 OHA 
59 45 male 3 B 130 300 3.19 4.32 73.84 563 OHA 
60 45 
femal
e 1 A 112 201 2.32 3.12 74.36 432 OHA 
61 41 male 4 B 120 192 2.35 3.2 73.44 563 INSULIN  
62 50 male 4 B 140 230 2.12 2.9 73.10 548 OHA 
63 46 
femal
e 1 A 130 215 2.3 3.12 73.72 431 OHA 
64 49 male 1 A 115 195 2.19 2.95 74.24 424 OHA 
65 47 
femal
e 2 A 125 205 2.28 3 76.00 424 OHA 
66 48 male 2 A 122 199 2.24 2.8 80.00 572 OHA 
67 48 
femal
e 1 A 110 185 2.24 2.72 82.35 427 OHA 
68 47 male 2 A 115 196 2.27 2.7 84.07 574 OHA 
69 49 
femal
e 3 B 125 186 2.14 2.7 79.26 420 OHA 
70 46 male 2 A 126 305 2.3 2.95 77.97 575 OHA 
71 48 
femal
e 4 B 135 145 2.19 2.92 75.00 402 INSULIN  
72 47 male 4 B 136 255 2.22 2.85 77.89 554 INSULIN  
73 51 male 2 A 120 195 2.15 2.75 78.18 565 OHA 
74 52 
femal
e 3 B 126 245 2.07 2.6 79.62 400 OHA 
75 52 male 2 A 120 215 3.08 3.8 81.05 563 OHA 
76 54 
femal
e 4 B 135 210 2.61 3.3 79.09 389 INSULIN  
77 55 male 2 A 110 220 2.93 3.45 84.93 553 OHA 
78 53 
femal
e 4 B 128 180 2.96 3.36 88.10 393 OHA 
79 51 male 4 B 136 236 3.03 3.75 80.80 545 OHA 
80 52 
femal
e 4 B 130 250 2.98 3.46 86.13 395 OHA 
81 52 male 4 B 134 210 3.01 4 75.25 542 INSULIN  
82 54 
femal
e 6 C 160 240 1.68 2.2 76.36 374 OHA 
83 55 male 6 C 155 221 2.58 3.36 76.79 518 OHA 
84 51 male 2 A 135 201 3.06 3.98 76.88 565 OHA 
85 53 
femal
e 5 C 144 225 2.66 3.55 74.93 383 OHA 
86 55 male 1 A 145 230 2.93 3.45 84.93 558 OHA 
87 56 
femal
e 5 C 152 245 2.6 3.41 76.25 375 OHA 
88 57 
femal
e 6 C 160 275 1.64 2.31 71.00 373 OHA 
89 58 
femal
e 7 C 165 246 1.6 2.41 66.39 466 INSULIN  
90 60 
femal
e 7 C 180 275 1.57 2.12 74.06 370 OHA 
91 56 male 1 A 95 145 2.02 2.51 80.48 555 OHA 
92 56 male 5 C 140 196 2.55 3.12 81.73 520 INSULIN  
93 57 male 6 C 150 220 2.51 3.02 83.11 515 OHA 
94 57 male 7 C 156 230 2.5 3.16 79.11 510 INSULIN  
95 58 male 5 C 145 199 2.48 3.02 82.12 513 INSULIN  
96 58 male 6 C 140 210 2.45 3.12 78.53 508 INSULIN  
97 59 male 7 C 138 205 2.42 3.12 77.56 504 INSULIN  
98 59 male 5 C 140 185 2.43 3.23 75.23 498 OHA 
99 60 male 7 C 145 235 2.4 3.12 76.92 502 OHA 
100 60 male 7 C 150 265 2.4 3.16 75.95 502 OHA 
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